Pancreatic cancer genomics

Current Opinion in Genetics and Development

Volumn 24, Issue 1, 2014, Pages 74-81

  Chang, David K ^a,b,c,d,e,f   Grimmond, Sean M ^a,g   Biankin, Andrew V ^a,b,c,d,e,f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELANOMA ANTIGEN; MELANOMA ANTIGEN 6; MITOMYCIN; MIXED LINEAGE LEUKEMIA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53; SMAD4 PROTEIN; SOLUTE CARRIER FAMILY 16 MEMBER 4; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRASTUZUMAB; UNCLASSIFIED DRUG; ZINC FINGER IMPRINTED 2; ZINC FINGER PROTEIN;

CANCER GENETICS; CANCER MORTALITY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; DNA MICROARRAY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; GENOMICS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 84893017766     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2013.12.001     Document Type: Review

References (56)

1. Samuel N., Hudson T.J. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2012, 9:77-87.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Biankin A.V., Hudson T.J. Somatic variation and cancer: therapies lost in the mix. Hum Genet 2011, 130:79-91.
4. Hudson T.J., Anderson W., Artez A., Barker A.D., Bell C., Bernabe R.R., Bhan M.K., Calvo F., Eerola I., Gerhard D.S., et al. International network of cancer genome projects. Nature 2010, 464:993-998.
5. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
6. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405.
7. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
8. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsberger L.A., Latimer C., McLaren S., Lin M.L., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
9. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
10. Song S., Nones K., Miller D., Harliwong I., Kassahn K.S., Pinese M., Pajic M., Gill A.J., Johns A.L., Anderson M., et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One 2012, 7:e45835.
11. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
12. Dees N.D., Zhang Q., Kandoth C., Wendl M.C., Schierding W., Koboldt D.C., Mooney T.B., Callaway M.B., Dooling D., Mardis E.R., et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012, 22:1589-1598.
13. Biankin A.V., Grimmond S.M. Novel cancer drivers: mining the kinome. Genome Med 2013, 5:19.
14. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
15. Boehm J.S., Hahn W.C. Towards systematic functional characterization of cancer genomes. Nat Rev Genet 2011, 12:487-498.
16. Cheung H.W., Cowley G.S., Weir B.A., Boehm J.S., Rusin S., Scott J.A., East A., Ali L.D., Lizotte P.H., Wong T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011, 108:12372-12377.
17. Chin L., Andersen J.N., Futreal P.A. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011, 17:297-303.
18. Eifert C., Powers R.S. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer 2012, 12:572-578.
19. Perez-Mancera P.A., Rust A.G., van der Weyden L., Kristiansen G., Li A., Sarver A.L., Silverstein K.A., Grutzmann R., Aust D., Rummele P., et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012, 486:266-270.
20. Mann K.M., Ward J.M., Yew C.C., Kovochich A., Dawson D.W., Black M.A., Brett B.T., Sheetz T.E., Dupuy A.J., Chang D.K., et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2012, 109:5934-5941.
21. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993.
22. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
23. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Campbell P.J., Stratton M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013, 3:246-259.
24. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
25. Klein A.P. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 2013, 13:66-74.
26. Couch F.J., Johnson M.R., Rabe K.G., Brune K., de Andrade M., Goggins M., Rothenmund H., Gallinger S., Klein A., Petersen G.M., et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:342-346.
27. Martin S.T., Matsubayashi H., Rogers C.D., Philips J., Couch F.J., Brune K., Yeo C.J., Kern S.E., Hruban R.H., Goggins M. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 2005, 24:3652-3656.
28. Jones S., Hruban R.H., Kamiyama M., Borges M., Zhang X., Parsons D.W., Lin J.C., Palmisano E., Brune K., Jaffee E.M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
29. Roberts N.J., Jiao Y., Yu J., Kopelovich L., Petersen G.M., Bondy M.L., Gallinger S., Schwartz A.G., Syngal S., Cote M.L., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012, 2:41-46.
30. Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Boige V., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013, 31:23-29.
31. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
32. ASCO Accelerating progress against cancer: ASCO's blueprint for transforming clinical and translational cancer research 2011.
33. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat Med 2013, 19:655.
34. Showalter S.L., Charles S., Belin J., Cozzitorto J., Einstein P., Richards N.G., Sauter P.K., Kennedy E.P., Witkiewicz A., Brody J.R., et al. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv 2010, 7:273-284.
35. Nakano Y., Tanno S., Koizumi K., Nishikawa T., Nakamura K., Minoguchi M., Izawa T., Mizukami Y., Okumura T., Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007, 96:457-463.
36. Mori R., Ishikawa T., Ichikawa Y., Taniguchi K., Matsuyama R., Ueda M., Fujii Y., Endo I., Togo S., Danenberg P.V., et al. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 2007, 17:1201-1205.
37. Garcia-Manteiga J., Molina-Arcas M., Casado F.J., Mazo A., Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003, 9:5000-5008.
38. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., Cass C., Lai R., Mackey J.R. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004, 10:6956-6961.
39. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., Orlandini C., Boggi U., Campani D., Del Chiaro M., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006, 66:3928-3935.
40. Marechal R., Mackey J.R., Lai R., Demetter P., Peeters M., Polus M., Cass C.E., Young J., Salmon I., Deviere J., et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009, 15:2913-2919.
41. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., Abrams R., Benson A.B., Macdonald J., Cass C.E., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136:187-195.
42. Xia B., Dorsman J.C., Ameziane N., de Vries Y., Rooimans M.A., Sheng Q., Pals G., Errami A., Gluckman E., Llera J., et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007, 39:159-161.
43. Byrski T., Huzarski T., Dent R., Gronwald J., Zuziak D., Cybulski C., Kladny J., Gorski B., Lubinski J., Narod S.A. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 115:359-363.
44. Tabernero J., Macarulla T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 2009, 27:5487-5491.
45. Ciliberto D., Botta C., Correale P., Rossi M., Caraglia M., Tassone P., Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013, 49:593-603.
46. van der Heijden M.S., Brody J.R., Dezentje D.A., Gallmeier E., Cunningham S.C., Swartz M.J., DeMarzo A.M., Offerhaus G.J., Isacoff W.H., Hruban R.H., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005, 11:7508-7515.
47. van der Heijden M.S., Brody J.R., Gallmeier E., Cunningham S.C., Dezentje D.A., Shen D., Hruban R.H., Kern S.E. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004, 165:651-657.
48. Isacoff W.H., Bendetti J.K., Barstis J.J., Jazieh A.R., Macdonald J.S., Philip P.A. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol 2007, 25:1665-1669.
49. Von Hoff D., Ervin T., Arena F., Chiorean E., Infante J., Moore M. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 2013, 31.
50. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
51. Kimura K., Sawada T., Komatsu M., Inoue M., Muguruma K., Nishihara T., Yamashita Y., Yamada N., Ohira M., Hirakawa K. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006, 12:4925-4932.
52. Safran H., Iannitti D., Ramanathan R., Schwartz J.D., Steinhoff M., Nauman C., Hesketh P., Rathore R., Wolff R., Tantravahi U., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004, 22:706-712.
53. Harder J., Ihorst G., Heinemann V., Hofheinz R., Moehler M., Buechler P., Kloeppel G., Rocken C., Bitzer M., Boeck S., et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012, 106:1033-1038.
54. Chou A., Waddell N., Cowley M.J., Gill A., Chang D.K., Patch A.M., Nones K., Wu J., Pinese M., Johns A.L., et al. Clinical features of HER2 amplified pancreatic cancer. Genome Med 2013.
55. Klumpen H.J., Queiroz K.C., Spek C.A., van Noesel C.J., Brink H.C., de Leng W.W., de Wilde R.F., Mathus-Vliegen E.M., Offerhaus G.J., Alleman M.A., et al. mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. J Clin Oncol 2011, 29:e150-e153.
56. Yap T.A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R.D., Delgado L., Taylor A., Lupinacci L., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695.